Compare Amphastar Pharmaceuticals Inc (AMPH) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Omnicom Group Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Omnicom Group Inc. trades at $85.75 (market cap $23.22B). The key difference: Omnicom Group Inc. is far larger — about 26.9× Amphastar Pharmaceuticals Inc's market cap, and Omnicom Group Inc. pays a 3.78% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | OMC | |
|---|---|---|
Market Cap | $863.95M | $23.22B |
Sector | Health | Media |
52-Week High | $30.81 | $86.22 |
52-Week Low | $16.87 | $67.27 |
Enterprise Value | $1.26B | $31.30B |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Omnicom Group (OMC) trades at $85.24, up 3.31% today, with a bullish technical outlook supported by moving averages and key resistance at $86. Recent Q2 2026 earnings beat estimates with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company maintains a $0.80 quarterly dividend and benefits from post-merger synergies with Interpublic Group.
OMC presents a value opportunity with a low P/S of 0.96 and consensus price target of $107, but high P/E of 230.38 and integration risks post-acquisition warrant caution. Analyst sentiment is mixed with 32% buy ratings, highlighting growth potential against margin pressures and competitive threats in the advertising sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
